Neuralstem Announces Presentation of Clinical Data for NSI-189 in Major Depressive Disorder at the Upcoming American College of Neuropsychopharmacology Annual Meeting
GERMANTOWN, Md., Nov. 16, 2017 (GLOBE NEWSWIRE) — Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company developing novel treatments for nervous system diseases, today announced that data from the Company’s Phase 2 study of NSI-189 in patients with major depressive disorder will be presented at the 56th American College of Neuropsychopharmacology (ACNP) Annual Meeting, which is being held […]